Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
PubMed , Bioscience Reports , vol
Healthcare providers must weigh the risks and benefits of prescribing GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors to patients with pancreatitis, particularly those with a history of pancreatic disorders
The findings shed light on the barriers that people with obesity experience in accessing weight-loss treatment in a healthcare system that often views obesity as a risk factor for other diseases that should be managed through lifestyle changes alone
adults from 2002 to 2012
US$ 21.90
US$ 20.31
US$ 28.88
US$ 20.94
US$ 21.92
US$ 24.69
US$ 25.35
US$ 27.84
US$ 26.60
